Retatrutide (investigational)
retatrutide · GIP / GLP-1 / glucagon triple receptor agonist · Eli Lilly
In short
Retatrutide is an investigational GIP / GLP-1 / glucagon triple receptor agonist from Eli Lilly. It is not approved and cannot legally be bought outside a registered clinical trial. Not FDA-approved. Lilly plans to submit to the FDA in Q1 2027 after positive TRIUMPH-2 and TRIUMPH-3 results (July 2026).
What it is used for
- In phase 3 trials for obesity, knee osteoarthritis pain and sleep apnea
Retatrutide dosage
Per the official label. Your prescriber sets your dose — never change it on your own.
| 1Status | No approved dosing — investigational |
|---|
How to take it
Not available outside clinical trials.
Storage
—
How it works
Safety
Safety data come from clinical trials only. Gastrointestinal effects were the most common, as with other incretin medicines.
Cost
No price until approval.
Can you buy Retatrutide?
No. It is not approved, so there is no legal way to purchase or order it outside a registered clinical trial. Search ClinicalTrials.gov for trials near you.
Frequently asked questions
Is 'research peptide' retatrutide legal?
It is not an approved drug. The FDA sent warning letters in August 2026 to online sellers marketing retatrutide, semaglutide and tirzepatide products.
Also searched as: retatrutide FDA approval, retatrutide release date, triple G, retatrutide results, Retatrutid, reta
Sources
Checked against these primary sources on .